These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 12835708)

  • 1. HIV vaccines 1983-2003.
    McMichael AJ; Hanke T
    Nat Med; 2003 Jul; 9(7):874-80. PubMed ID: 12835708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
    Goepfert PA; Tomaras GD; Horton H; Montefiori D; Ferrari G; Deers M; Voss G; Koutsoukos M; Pedneault L; Vandepapeliere P; McElrath MJ; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Baden LR; Harro C; Evans T;
    Vaccine; 2007 Jan; 25(3):510-8. PubMed ID: 17049679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
    McMichael A; Hanke T
    Nat Rev Immunol; 2002 Apr; 2(4):283-91. PubMed ID: 12001999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New hope for an AIDS vaccine.
    Robinson HL
    Nat Rev Immunol; 2002 Apr; 2(4):239-50. PubMed ID: 12001995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV/AIDS vaccines: 2007.
    Robinson HL
    Clin Pharmacol Ther; 2007 Dec; 82(6):686-93. PubMed ID: 17971817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
    Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
    J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines.
    Robinson HL; Weinhold KJ
    J Infect Dis; 2006 Dec; 194(12):1625-7. PubMed ID: 17109331
    [No Abstract]   [Full Text] [Related]  

  • 8. Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques.
    De Rose R; Chea S; Dale CJ; Reece J; Fernandez CS; Wilson KM; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Sullivan MT; Kent SJ
    Vaccine; 2005 Mar; 23(16):1949-56. PubMed ID: 15734067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Policy rebuttal. HIV vaccine trial justified.
    McNeil JG; Johnston MI; Birx DL; Tramont EC
    Science; 2004 Feb; 303(5660):961. PubMed ID: 14963313
    [No Abstract]   [Full Text] [Related]  

  • 10. Hitting HIV where it hurts: an alternative approach to HIV vaccine design.
    Altfeld M; Allen TM
    Trends Immunol; 2006 Nov; 27(11):504-10. PubMed ID: 16997629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV vaccines. Viral envelope fails to deliver?
    Bolognesi DP; Matthews TJ
    Nature; 1998 Feb; 391(6668):638-9. PubMed ID: 9490406
    [No Abstract]   [Full Text] [Related]  

  • 12. HIV vaccine efficacy trials: towards the future of HIV prevention.
    Kim D; Elizaga M; Duerr A
    Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AIDS vaccines: back to 'plan A'.
    Check E
    Nature; 2003 Jun; 423(6943):912-4. PubMed ID: 12827164
    [No Abstract]   [Full Text] [Related]  

  • 14. Measuring HIV-1-specific T cell immunity: how valid are current assays?
    D'Souza MP; Altfeld M
    J Infect Dis; 2008 Feb; 197(3):337-9. PubMed ID: 18184092
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is an HIV vaccine possible?
    McMichael AJ; Hanke T
    Nat Med; 1999 Jun; 5(6):612-4. PubMed ID: 10371492
    [No Abstract]   [Full Text] [Related]  

  • 17. Current strategies and limitations of HIV vaccines.
    Kawalekar OU; Shedlock DJ; Weiner DB
    Curr Opin Investig Drugs; 2010 Feb; 11(2):192-202. PubMed ID: 20112169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of an AIDS vaccine: status report].
    Girard MP
    Med Trop (Mars); 2007 Aug; 67(4):340-6. PubMed ID: 17926791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [HIV/AIDS vaccines: heading for new vaccine approaches?].
    Girard MP
    Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env(311-320) virus.
    Cukalac T; Moffat JM; Venturi V; Davenport MP; Doherty PC; Turner SJ; Stambas J
    Vaccine; 2009 Nov; 27(48):6755-61. PubMed ID: 19744584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.